constipation but their relative clinical performance is unclear. Our aim was to investigate the diagnostic yield and clinical outcomes of DFP and ARM in chronic constipation.

Methods Patients who had undergone both DFP and ARM over a 3-year period were studied retrospectively. Demographics, treatment and clinical outcomes were recorded. The diagnosis was recorded as “mixed” if investigation showed evidence of both anismus and anatomical problems such as rectocoele, intussusception or prolapse. The clinical outcome was defined as positive if the test resulted in treatment with symptomatic improvement, or resolution at follow-up. To determine whether there was a selection bias in those undergoing both DFP and ARM we additionally looked at the two groups having solely DFP or ARM from the same period.

Results DFP and ARM group: 45 patients (40 female, 58% surgical referrals; age range 17–85 years; median 46) underwent both DFP and ARM. The diagnostic yield for DFP was higher at 98% (anismus 44%, anatomical 40%, mixed 14%; normal 2%) vs 47% for ARM (anismus 26%, mixed 21%; normal 55%). There was diagnostic discordance in only 11 (26%), partial discordance in 9 (21%) and discordance in 23 (53%) patients. Although the diagnostic yield of DFP was much greater than ARM in this combined group, both tests led to similar positive outcomes regardless (47% in DFP vs 45% in ARM) when tests revealed a pathology. Single investigation groups: 10 patients had DFP alone (8 female, 60% surgical referrals; age range 22–73 years, median 55) with a diagnostic yield of 90% (anismus 50%, anatomical 50%, mixed 10%; normal 10%). The positive outcome in those with a detectable pathology was 33%. 15 patients had ARM alone (14 female, 27% surgical referrals; age range 19–75 years, median 50) with a diagnostic yield of 67% (anismus; 33%; normal). The positive outcome in those with a detectable pathology was 70%.

Conclusion DFP had a higher diagnostic yield than ARM, but concordance was poor. Greater diagnostic yield did not translate into more positive clinical outcomes either. The clinical impact of additional DFP-based diagnoses is therefore questionable. The single test cohort data suggest that patients having DFP alone are a different clinical population from those who accessed both tests, since diagnostic yields and clinical outcomes were higher for ARM alone. The latter group were predominantly medical gastroenterology referrals. Further study is required to design optimal investigation strategies for chronic constipation.

Competing interests None declared.

Oesophageal II

PWE-008 DO STATINS PREVENT THE HISTOLOGICAL SUBTYPES OF OESEPHAGEAL CANCER? PROSPECTIVE DATA FROM THE UK GENERAL PRACTICE RESEARCH DATABASE (GPRD)

doi:10.1136/gutjnl-2012-302514d.8

1H Y Bhutta, 2,3L Alexandre,* 3A Clark, 4S Holt, 1,3M Lewis, 2,3A Hart. 1Department of General Surgery, Norfolk and Norwich Hospital, Norwich, UK; 2Department of Gastroenterology, Norfolk and Norwich Hospital, Norwich, UK; 3Norwich Medical School, University of East Anglia, Norwich, UK; 4Roundwell Medical Centre, Norwich, UK

Introduction The incidence of oesophageal adenocarcinoma (OAC) has risen dramatically in the Western world and is associated with a poor prognosis. Statins show anti-cancer properties in experimental work with OAC cell lines for example reduced cell proliferation, increased apoptosis. This study aimed to investigate if statins are negatively associated with the development of two different histological subtypes of oesophageal cancer, OAC and oesophageal squamous cell cancer (OSCC), in a prospective cohort study.

Methods The cohort was over 4 million people in the General Practice Research Database (GPRD), a UK database of 488 nationwide general practices. Information is recorded on medication use prior to development of other illnesses, including cancers. Statin use was defined as a prescription for a minimum of 10 months preceding diagnosis of oesophageal cancer. Approximately half the GP practices in the GPRD are linked to the NHS cancer registry, allowing identification and sub-classification of histologically confirmed cases of OAC and OSCC. Each case was matched with four controls and conditional logistic regression estimated the OR plus 95% CIs for statin use and OAC or OSCC.

Results 581 histologically confirmed cases of OAC (77.8% men, mean age 70.7 years, SD=11.4) and 332 cases of OSCC (38.6% men,
71.9 years, SD=12.3) were identified between 2000 and 2008. The median length of statin use in cases and controls prior to diagnosis or index date was 5.9 years (IQR 2.3–6.1 years). Analysis by histological subtype showed an inverse association for OAC (OR 0.61, 95% CI 0.39 to 0.94) and for OSCC (OR 0.41, 95% CI 0.21 to 0.80). Categorisation into lipophilic and hydrophilic statins demonstrated significant inverse associations for only lipophilic statins for both OAC (OR 0.60, 95% CI 0.38 to 0.95) and OSCC (OR 0.46, 95% CI 0.25 to 0.91). There was a dose-response effect for statins and both OAC and OSCC (p<0.05 for linear trend) comparing high and low-dose statin use.

**Conclusion** The data supports lipophilic statins having a protective effect against the development of both OAC and OSCC, with evidence of a dose-response trend. Confirmation in other populations is required. Detailed statin use, according to class and dose, should be measured in future aetiological studies of both OAC and OSCC. The information supports assessment of these drugs in chemoprevention of OAC in the general population and those with Barrett’s oesophagus in clinical trials.

**Competing interests** None declared.

---

**PWE-009**

**DIETARY DOCOSAHEXAENOIC ACID IS INVERSELY ASSOCIATED WITH THE RISK OF DEVELOPING OESOPHAGEAL ADENOCARCINOMA: A UK PROSPECTIVE STUDY IN THE EPIC-NORFOLK COHORT, USING INFORMATION FROM 7-DAY FOOD DIARIES**

doi:10.1136/gutjnl-2012-302514d.9

1,2L Alexandre,* 1,2M Yates, 3R Luben, 2E Cheong, 2L Igali, 4R Fitzgerald, 3K-T Khaw, 1,2A Hart. 1Norwich Medical School, University of East Anglia, Norwich, UK; 2Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, UK; 3Strangeways Research Laboratory, University of Cambridge, Cambridge; 4Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK

**Introduction** Dietary docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are both n-3 polyunsaturated fatty acids (n3 PUFAs) which have both anti-inflammatory and anti-carcinogenic actions, including inhibiting angiogenesis and tumour cell proliferation, and promoting apoptosis. The aim of this study was to conduct the first epidemiological investigation to determine if there is an inverse association between DHA and EPA intake and the risk of developing both Barrett’s oesophagus (BO) and oesophageal adenocarcinoma (OAC).

**Methods** A total of 25 639 men and women aged 40–75 years, were recruited between the years 1993 and 1997 into the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort Study. At baseline, participants completed detailed 7-day food diaries which were coded by nutritionists. Subjects were followed-up over subsequent years for the development of BO and OAC. A review of case notes confirmed these diagnoses. Dietary intakes were compared between cases and a random sample of 5 797 controls in a case-cohort analysis. Cox regression estimated the HR for both campesterol and total PS.

**Results** During follow-up, 104 patients were diagnosed with BO (80% men, median age 67.0 yrs [IQR 61.1–73.1] at diagnosis) after a median follow-up of 6.2 yrs (IQR 4.1–8.1). A further 63 patients developed OAC (53% men, median age 73.0 yrs [IQR 67.0–78.0] at diagnosis) after a median follow-up of 6.4 yrs (IQR 4.4–8.9). For BO, no significant associations were found with campesterol (HR 1.47, 95% CI 0.77 to 2.79) or total dietary PS (HR 1.28, 95% CI 0.70 to 2.23), in either sex. For OAC, in men, there were inverse associations with campesterol (HR 0.43, 95% CI 0.22 to 0.83, p=0.01), in a threshold manner, comparing the lowest with a summation of the top four quintiles of intake. In women, for OAC, there were no such associations with campesterol (HR 2.13, 95% CI 0.44 to 10.15, p=0.34). Total PS intake (HR 0.71, 95% CI 0.38 to 1.35) was not significantly associated with OAC in either sex.

**Conclusion** Campesterol intake was associated with an approximate 55% risk reduction for OAC in men, although there were no significant effects in BO or for either condition in women. The data support a role for dietary campesterol, in preventing the malignant transformation of BO to OAC, and therefore these micronutrients should be measured in future aetiological studies of OAC.

**Competing interests** None declared.

---

**PWE-010**

**DIETARY CAMPESTEROL IS INVERSELY ASSOCIATED WITH THE RISK OF DEVELOPING OESOPHAGEAL ADENOCARCINOMA: A UK PROSPECTIVE STUDY IN THE EPIC-NORFOLK COHORT, USING INFORMATION FROM 7-DAY FOOD DIARIES**

doi:10.1136/gutjnl-2012-302514d.10

1,2L Alexandre,* 1,2M Yates, 3R Luben, 2E Cheong, 2L Igali, 4R Fitzgerald, 3K-T Khaw, 1,2A Hart. 1Norwich Medical School, University of East Anglia, Norwich, UK; 2Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, UK; 3Strangeways Research Laboratory, University of Cambridge, Cambridge; 4Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK

**Introduction** Dietary phytoestrogens (FS), including campesterol, the most bioavailable of this group, are structurally similar to cholesterol, and are present in grain legumes, cereals, nuts and vegetable oils. Experimental studies have shown FS have several anti-carcinogenic effects, including inducing apoptosis and inhibiting both angiogenesis and cell proliferation. The aim of this study was to conduct the first epidemiological investigation to determine if an inverse association exists between FS intake and the risk of both Barrett’s oesophagus (BO) and oesophageal adenocarcinoma (OAC).

**Methods** A total of 25 639 men and women aged 40–75 years, were recruited between the years 1993 and 1997 into the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort Study. At baseline, participants completed detailed 7-day food diaries which were coded by nutritionists. Subjects were followed-up over subsequent years for the development of BO and OAC. A review of case notes confirmed these diagnoses. Dietary intakes were compared between cases and a random sample of 5 797 controls in a case-cohort analysis. Cox regression estimated the HR for both campesterol and total FS.

**Results** During follow-up, 104 patients were diagnosed with BO (80% men, median age 67.0 yrs [IQR 61.1–73.1] at diagnosis) after a median follow-up of 6.2 yrs (IQR 4.1–8.1). A further 63 patients developed OAC (53% men, median age 73.0 yrs [IQR 67.0–78.0] at diagnosis) after a median follow-up of 6.4 yrs (IQR 4.4–8.9). For BO, no significant associations were found with campesterol (HR 1.47, 95% CI 0.77 to 2.79) or total dietary PS (HR 1.28, 95% CI 0.70 to 2.23), in either sex. For OAC, in men, there were inverse associations with campesterol (HR 0.43, 95% CI 0.22 to 0.83, p=0.01), in a threshold manner, comparing the lowest with a summation of the top four quintiles of intake. In women, for OAC, there were no such associations with campesterol (HR 2.13, 95% CI 0.44 to 10.15, p=0.34). Total FS intake (HR 0.71, 95% CI 0.38 to 1.35) was not significantly associated with OAC in either sex.

**Conclusion** Campesterol intake was associated with an approximate 55% risk reduction for OAC in men, although there were no significant effects in BO or for either condition in women. The data support a role for dietary campesterol, in preventing the malignant transformation of BO to OAC, and therefore these micronutrients should be measured in future aetiological studies of OAC.

**Competing interests** None declared.